Bubendorf, Switzerland, Monday, January 12, 2015 – CIS Pharma has taken a strategic decision to extend its activity into the field of cancer treatments. The defined objective is to improve the potency of antibody-drug conjugates (ADCs). Having established a number of lead materials, the research team is now developing drug carriers that offer higher drug load per antibody as compared to current ADC designs. In addition, specific linker chemistry is being developed for use with the carrier. The drug carriers are based on the proprietary Cellophil® Smart Polymer technology that allows the ADCs to be custom designed for delivery of a wide array of anti-tumor agents directly to the cancerous cells. For proof of concept studies, CIS Pharma is collaborating with NBE Therapeutics based in Basel, Switzerland.